title: Echocardiographic evaluation of patients cured of childhood cancer: a single center study of 117 subjects who received anthracyclines.
abstract: BACKGROUND
  The risk of cardiomyopathy following exposure to anthracycline in asymptomatic long-term survivors of childhood cancer is still hard to predict and precisely quantify. To identify the impact of different cumulative doses, even within a non-high dose range, and the echocardiographic parameters suitable for evaluating cardiac function, we studied diastolic and systolic echocardiographic parameters in a cohort of patients followed in a single center.
  
  
  METHODS
  A total of 117 subjects were studied at a median time of 7 years after treatment completion. A complete M-mode, two-dimensional and Doppler echocardiographic study was obtained at rest in all patients according to the standard recommendations of the American Society of Echocardiography.
  
  
  RESULTS
  Ninety-nine patients (85%) had completely normal cardiac function, while 18 had abnormal echocardiographic findings: 12 had one abnormal value, 5 had two, and 1 had three abnormal values. All the changes were in left ventricular dimensions, wall thickness or indices of systolic function; no alterations in left ventricular diastolic function parameters were found. None of the echocardiographic parameters correlated significantly with the cumulative dose of anthracyclines administered either at univariate analysis or after adjusting for sex, body surface area or considered risk factors.
  
  
  CONCLUSIONS
  Subjects exposed to a median cumulative dose of 214 mg/m(2) had no echographic abnormalities a median of 7 years later. We did not find any correlation between cumulative anthracycline dose and the echocardiographic parameters tested. We now offer echocardiographic follow-up to patients with mildly reduced fractional shortening and/or ejection fraction to rule out late onset dysfunction.
authors.affiliation: Department of Pediatrics, IRCCS Policlinico, S. Matteo, Pavia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Bossi
authors.forename: L
authors.initials: L
authors.lastname: Lanzarini
authors.forename: M L
authors.initials: ML
authors.lastname: Laudisa
authors.forename: C
authors.initials: C
authors.lastname: Klersy
authors.forename: A
authors.initials: A
authors.lastname: Raisaro
authors.forename: M
authors.initials: M
authors.lastname: Aricò
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003971:Diastole; D015150:Echocardiography, Doppler; D005260:Female; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D017741:Survivors; D016277:Ventricular Function, Left
chemical_list: D000903:Antibiotics, Antineoplastic